WO2010127272A3 - Hydroxyethylamino sulfonamide derivatives - Google Patents

Hydroxyethylamino sulfonamide derivatives Download PDF

Info

Publication number
WO2010127272A3
WO2010127272A3 PCT/US2010/033206 US2010033206W WO2010127272A3 WO 2010127272 A3 WO2010127272 A3 WO 2010127272A3 US 2010033206 W US2010033206 W US 2010033206W WO 2010127272 A3 WO2010127272 A3 WO 2010127272A3
Authority
WO
WIPO (PCT)
Prior art keywords
sulfonamide derivatives
compound
hydroxyethylamino sulfonamide
hydroxyethylamino
compositions
Prior art date
Application number
PCT/US2010/033206
Other languages
French (fr)
Other versions
WO2010127272A2 (en
Inventor
Scott L. Harbeson
Roger D. Tung
Julie F. Liu
Craig E. Masse
Original Assignee
Concert Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concert Pharmaceuticals, Inc. filed Critical Concert Pharmaceuticals, Inc.
Publication of WO2010127272A2 publication Critical patent/WO2010127272A2/en
Publication of WO2010127272A3 publication Critical patent/WO2010127272A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

This invention relates to novel hydroxyethylamino sulfonamides, their derivatives, pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a compound with the ability to act as an HIV (human immunodeficiency virus) protease inhibitor.
PCT/US2010/033206 2009-04-30 2010-04-30 Hydroxyethylamino sulfonamide derivatives WO2010127272A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21497709P 2009-04-30 2009-04-30
US61/214,977 2009-04-30

Publications (2)

Publication Number Publication Date
WO2010127272A2 WO2010127272A2 (en) 2010-11-04
WO2010127272A3 true WO2010127272A3 (en) 2011-04-21

Family

ID=42244939

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/033206 WO2010127272A2 (en) 2009-04-30 2010-04-30 Hydroxyethylamino sulfonamide derivatives

Country Status (2)

Country Link
US (1) US20100305173A1 (en)
WO (1) WO2010127272A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8592487B2 (en) * 2007-10-26 2013-11-26 Concert Pharmaceuticals, Inc. Deuterated darunavir
US20090131363A1 (en) * 2007-10-26 2009-05-21 Harbeson Scott L Deuterated darunavir
AR080375A1 (en) 2010-03-05 2012-04-04 Sanofi Aventis PROCEDURE FOR THE PREPARATION OF 2- (CYCLOHEXIMETHYL) -N- {2 - [(2S) -1-METHYLPIRROLIDIN-2-IL] ETIL} -1,2,3,4-TETRAHYDROISOCHINOLINE- 7-SULFONAMIDE
US20140213553A1 (en) * 2011-05-03 2014-07-31 Concert Pharmaceuticals Inc. Carbamoylpyridone derivatives

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995026325A2 (en) * 1994-03-25 1995-10-05 Isotechnika Inc. Enhancement of the efficacy of drugs by deuteration
US20050267074A1 (en) * 2004-05-07 2005-12-01 Sequoia Pharmaceuticals Resistance-repellent retroviral protease inhibitors
US20090076138A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched darunavir

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968942A (en) * 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
PT810209E (en) * 1992-08-25 2002-09-30 Searle & Co HYDROXYETHYLAMINO-SULFONAMIDES OF ALPHA- AND BETA-AMINOACIDOS UTEIS AS INHIBITORS OF RETROVIRAL PROTEASE
US7141609B2 (en) * 1992-08-25 2006-11-28 G.D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
PT1104760E (en) * 1999-12-03 2003-06-30 Pfizer Prod Inc SULFAMOYL-HETEROARILPIRAZOLE COMPOUNDS AS ANALGESIC AND ANTI-INFLAMMATORY AGENTS
EP1532127B1 (en) * 2002-06-27 2006-09-27 SmithKline Beecham Corporation PREPARATION OF STEREOISOMERS OF (3ALPHA, 3ALPHA/BETA, 6ALPHA/BETA) HEXAHYDROFURO(2,3-b) FURAN-3-OL
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
WO2005000249A2 (en) * 2003-06-27 2005-01-06 Smithkline Beecham Corporation Preparation of chemical compounds
RS51073B (en) * 2003-12-23 2010-10-31 Tibotec Pharmaceuticals Ltd. Process for the preparation of (3r,3as,6ar)-hexahydrofuro│2,3-b│ furan-3-yl (1s,2r)-3-││(4-aminophenyl) sulfonyl│(isobutyl), amino │-1-benzyl-2-2hydroxypropilcarbamate
EP1855672A4 (en) * 2005-03-11 2011-11-30 Glaxosmithkline Llc Hiv protease inhibitors
CA2624179A1 (en) * 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
US7750168B2 (en) * 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
MX2009002398A (en) * 2006-09-05 2009-03-16 Schering Corp Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis.
US8592487B2 (en) * 2007-10-26 2013-11-26 Concert Pharmaceuticals, Inc. Deuterated darunavir
US20090131363A1 (en) * 2007-10-26 2009-05-21 Harbeson Scott L Deuterated darunavir

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995026325A2 (en) * 1994-03-25 1995-10-05 Isotechnika Inc. Enhancement of the efficacy of drugs by deuteration
US20050267074A1 (en) * 2004-05-07 2005-12-01 Sequoia Pharmaceuticals Resistance-repellent retroviral protease inhibitors
US20090076138A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched darunavir

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MARC VERMEIR, SOPHIE LACHAU-DURAND, GEERT MANNENS, FILIP CUYCKENS, BART VA HOOF, ARAZ RAOOF: "Absorption, Metabolism, and Excretion of Darunavir, a New Protease Inhibitor, Administered Alone and with Low-Dose Ritonavir in Healthy Subjects", DMD FAST FORWARD, 24109, 8 January 2009 (2009-01-08), pages 1 - 54, XP002588463, DOI: 10.1124/dmd.108.024109 *

Also Published As

Publication number Publication date
WO2010127272A2 (en) 2010-11-04
US20100305173A1 (en) 2010-12-02

Similar Documents

Publication Publication Date Title
WO2009055006A8 (en) Deuterated darunavir
SA519402405B1 (en) Human immunodeficiency virus inhibitor compounds
PH12015501156A1 (en) Pharmaceutical compositions
PH12015502539B1 (en) Cenicriviroc compositions and methods of making and using the same
MD4754B1 (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
PH12015502056A1 (en) Benzothiazole compounds and their pharmaceutical use
WO2011007230A3 (en) Lupeol-type triterpene derivatives as antivirals
MX2013011691A (en) Inhibitors of viral replication, their process of preparation and their therapeutical uses.
MX2013012053A (en) Inhibitors of viral replication, their process of preparation and their therapeutical uses.
WO2011113060A3 (en) Antiviral compounds and methods of use thereof
WO2011150190A3 (en) Hcv inhibitor compounds and methods of use thereof
WO2012015986A3 (en) Substituted dioxopiperidinyl phthalimide derivatives
WO2013112959A8 (en) Antifibrotic compounds and uses thereof
WO2011160024A3 (en) Compounds useful as antiviral agents, compositions, and methods of use
EA201490223A1 (en) COMPOSITIONS BASED ON DARUNAVIR
EA201490222A1 (en) COMBINED COMPOSITIONS BASED ON DARUNAVIR
EP4342473A3 (en) Compounds useful in hiv therapy
MX2017003928A (en) Long acting pharmaceutical compositions.
MX2012001691A (en) Orally disintegrating compositions of linaclotide.
WO2011076367A3 (en) Synergistic antiviral composition and use thereof
WO2010047819A8 (en) Hydroxyethylamino sulfonamide derivatives
WO2010127272A3 (en) Hydroxyethylamino sulfonamide derivatives
WO2008133759A3 (en) Antiviral peptides
EA201590678A1 (en) CONNECTIONS FOR THE TREATMENT OF THE BLOCADE OF REMIELINIZATION IN DISEASES RELATED TO THE EXPRESSION OF THE PROTECTIVE PROTEIN
WO2009148600A3 (en) Deuterated lysine-based compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10719832

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10719832

Country of ref document: EP

Kind code of ref document: A2